British journal of pharmaceutical research, Jan 10, 2015
Background: statins are used routinely in patients with coronary artery disease for their lipid l... more Background: statins are used routinely in patients with coronary artery disease for their lipid lowering effects. Some clinical studies have found that statins do not affect clinical outcomes in patients with chronic heart failure (CHF), while others have found that statins have many beneficial effects. The aim of this study was to evaluate the pleiotropic effects of atorvastatin on patients with chronic heart failure of ischemic etiology (IHF) using conventional echocardiography and tissue doppler imaging. Patient & Methods: Fortyeight patients with (CHF) were divided randomly into two equal groups; Atorvastatin group (received conventional therapy of HF plus atorvastatin 20 mg/d orally) and Original Research Article El-Sisi et al.; BJPR, 6(5): 343-357, 2015; Article no.BJPR.2015.076 344 Control group (received conventional therapy only) for 3 months. Patients were examined both before and after treatment for biochemical tests; serum tumor necrosis factor α (TNFα), serum high sensetive c reactive protein (hsCRP), oxidized low density lipoprotein (ox LDL), noradrenaline, adrenaline, renin, brain naturetic peptide (BNP32), TroponinI, total lipid profile and malondialdehyde. Conventional Echocardiography including left ventricle (LV) dimensions & wall thickness, ejection fraction (EF), E/A ratio, and tissue Doppler imaging (TDI) including Isovolumic contraction (IC), mitral annulus systolic velocity(Speak), early (E) and late (A) diastolic peak velocities and Tei index were performed. Results: Atorvastatin group showed statistically significant decreased in TNF α, hsCRP, oxLDL, BNP32 and noradrenaline compared to their baseline values before the study. Conventional echo failed to detect significant changes in each group except for significant increase in E/A ratio in atorvastatin group. DTI demonstrated that atorvastatin group showed significant improvement in systolic function [significant increase in S wave & isovolumic contraction (IC) peak velocities and better diastolic function [E peak velocity increased & E/E' ratio decreased significantly]. Tei index and heart rate improved significantly in atorvastatin group. Conclusion: Atorvastatin improved cardiac function, decreased inflammatory and oxidative stress parameters as well as modulated the neurohormonal imbalance in CHF patients.
Introduction: Corona Virus induced disease – 2019 (COVID-19) disaster motivates scientific resear... more Introduction: Corona Virus induced disease – 2019 (COVID-19) disaster motivates scientific research to find a settling to this pandemic. With ending of 2021 year, various advances in immunotherapy against COVID-19 have emerged. Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Other antiviral therapy against COVID-19 includes Remdesivir and Favipravir. Aim of Study: To compare the efficacy and safety of casirivimab and imdevimab, Remdesivir and Favipravir as antiviral agents in hospitalized COVID19 patients. Patients and Population: 265 COVID-19 Polymerase Chain Reaction (PCR) positive patients are included in this study and will be assigned into 3 groups in a ratio of (1:2:2): 1- Group A: REGN3048-3051 2-group B: Remdesivir 3-group C: Favipravir Methods: Study design is single blind non-Randomized Controlled Trial (non-RCT). The duration of study is about 6 months after ethical approval. Results and discussi...
Background & objectives: Rheumatoid artherits (RA) is a refractory disease and the imbalance ... more Background & objectives: Rheumatoid artherits (RA) is a refractory disease and the imbalance between pro- and anti-inflammatory cytokines in favor of pro-inflammatory cytokines has been implicated in pathogenesis of RA. In this context, the aim of the present study was to compare the anti-inflammatory and antioxidant effects of candesartan, an angiotensin-receptor blocker, and atorvastatin in RA patients. Methods: In this single-blinded parallel randomized placebo controlled study, the patients recruited between December 2017 and May 2018 were categorized into three groups: group 1 included 15 RA patients who served as control group and received traditional therapy (+ placebo); group 2 included 15 RA patients who received traditional therapy + candesartan (8 mg/day); and group 3 included 15 patients who received traditional therapy + atorvastatin (20 mg/day) for three months. Clinical status in RA patients was evaluated by Disease Activity Score 28 (DAS28), Health Assessment Questionnaire-Disability Index (HAQ-DI) and morning stiffness before and three months after treatment. All groups were subjected to biochemical analysis of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β) and malondialdehyde (MDA) before and three months after treatment. Results: Both candesartan and atorvastatin treated groups showed significant decrease in serum levels IL-1β and TNF-α, acute-phase reactants (CRP and ESR), number of swollen joint and patient global assessment. This was also associated with improvement in disease activity and quality of life regarding DAS28 and HAQ-DI as compared to baseline data and the control group. Atorvastatin group showed significant decrease in the serum level of oxidative stress marker (MDA). Interpretation & conclusions: Both candesartan and atorvastatin showed anti-inflammatory effect and immunomodulatory effects leading to improvement in clinical status and disease activity in RA patients. However, atorvastatin was superior to candesartan through its anti-oxidant effect.
IntroductionCorona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to ... more IntroductionCorona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.Aim of Study1-To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID192-To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effectsPatients and Population265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is inc...
The development of drug resistance remains the major obstacle to clinical efficacy of cancer chem... more The development of drug resistance remains the major obstacle to clinical efficacy of cancer chemotherapy. Consequently, finding new therapeutic options for cancerous patients is an urgent need. Sixty newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients were recruited from Clinical Oncology Department, Faculty of Medicine, Menoufia University, Egypt prospectively randomized to three groups ( n = 20 for each group). Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the first five days of cycle}, group two received lansoprazole (LAN) 60 mg p.o. bid for only one week before starting each of cycle + R-CHOP and group three received famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R-CHOP for six cycles. Blood samples were obtained for biochemical analysis of transforming growth factor-β (TGF-β), Basic fibroblast growth factor (bFGF), interleukin-9 (IL-9), nuclear factor-kappa B (NF-κB) and Caspase 3 before and after six cycles of therapy. The obtained data showed that LAN and FAM resulted in significant decrease in (LDH, TGF-β, bFGF and IL-9, respectively) and significant increase in (Caspase-3). In addition, LAN produced a significant elevation in the response rate compared to the control group or the FAM group. Both LAN and FAM as adjuvant therapy represents a promising anticancer strategy in DLBCL by modulation of malignancy homeostasis mechanisms and boosting chemotherapy antitumor effects without further toxicity. In addition, LAN has a synergetic effect in improving the response rate. Trial registration Clinical Trial.gov Identifier: NCT0364707.
Asian Journal of Pharmaceutical and Clinical Research
Objective: Endothelial dysfunction is afflicted to the maturation of arteriosclerosis and type 2 ... more Objective: Endothelial dysfunction is afflicted to the maturation of arteriosclerosis and type 2 diabetes mellitus (T2DM) vascular complications. This study designed to evaluate the impact of fenofibrate adjuvant therapy on endothelial dysfunction and cardiovascular risk in patients with T2DM. Methods: Seventy-five subjects were recruited from the Internal Medicine Department of Tanta University Hospital. The participants were classified into three groups: Group 1 (control group), 25 healthy subjects; Group 2, 25 T2DM patients received glimepiride/metformin (2:500 mg/day); and Group 3, 25 T2DM patients received glimepiride/metformin (2:500 mg/day)+fenofibrate (300 mg/day). Patients were assessed before and 3 months after intervention for the determination of body mass index (BMI), blood pressure, glycemic picture (hemoglobin A1C % and homeostatic model assessment of insulin resistant), lipid panel, Castelli’s risk index (CRI-I and CRI-II), albumin-to-creatinine ratio (ACR), and endo...
British journal of pharmaceutical research, Jan 10, 2015
Background: statins are used routinely in patients with coronary artery disease for their lipid l... more Background: statins are used routinely in patients with coronary artery disease for their lipid lowering effects. Some clinical studies have found that statins do not affect clinical outcomes in patients with chronic heart failure (CHF), while others have found that statins have many beneficial effects. The aim of this study was to evaluate the pleiotropic effects of atorvastatin on patients with chronic heart failure of ischemic etiology (IHF) using conventional echocardiography and tissue doppler imaging. Patient & Methods: Fortyeight patients with (CHF) were divided randomly into two equal groups; Atorvastatin group (received conventional therapy of HF plus atorvastatin 20 mg/d orally) and Original Research Article El-Sisi et al.; BJPR, 6(5): 343-357, 2015; Article no.BJPR.2015.076 344 Control group (received conventional therapy only) for 3 months. Patients were examined both before and after treatment for biochemical tests; serum tumor necrosis factor α (TNFα), serum high sensetive c reactive protein (hsCRP), oxidized low density lipoprotein (ox LDL), noradrenaline, adrenaline, renin, brain naturetic peptide (BNP32), TroponinI, total lipid profile and malondialdehyde. Conventional Echocardiography including left ventricle (LV) dimensions & wall thickness, ejection fraction (EF), E/A ratio, and tissue Doppler imaging (TDI) including Isovolumic contraction (IC), mitral annulus systolic velocity(Speak), early (E) and late (A) diastolic peak velocities and Tei index were performed. Results: Atorvastatin group showed statistically significant decreased in TNF α, hsCRP, oxLDL, BNP32 and noradrenaline compared to their baseline values before the study. Conventional echo failed to detect significant changes in each group except for significant increase in E/A ratio in atorvastatin group. DTI demonstrated that atorvastatin group showed significant improvement in systolic function [significant increase in S wave & isovolumic contraction (IC) peak velocities and better diastolic function [E peak velocity increased & E/E' ratio decreased significantly]. Tei index and heart rate improved significantly in atorvastatin group. Conclusion: Atorvastatin improved cardiac function, decreased inflammatory and oxidative stress parameters as well as modulated the neurohormonal imbalance in CHF patients.
Introduction: Corona Virus induced disease – 2019 (COVID-19) disaster motivates scientific resear... more Introduction: Corona Virus induced disease – 2019 (COVID-19) disaster motivates scientific research to find a settling to this pandemic. With ending of 2021 year, various advances in immunotherapy against COVID-19 have emerged. Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Other antiviral therapy against COVID-19 includes Remdesivir and Favipravir. Aim of Study: To compare the efficacy and safety of casirivimab and imdevimab, Remdesivir and Favipravir as antiviral agents in hospitalized COVID19 patients. Patients and Population: 265 COVID-19 Polymerase Chain Reaction (PCR) positive patients are included in this study and will be assigned into 3 groups in a ratio of (1:2:2): 1- Group A: REGN3048-3051 2-group B: Remdesivir 3-group C: Favipravir Methods: Study design is single blind non-Randomized Controlled Trial (non-RCT). The duration of study is about 6 months after ethical approval. Results and discussi...
Background & objectives: Rheumatoid artherits (RA) is a refractory disease and the imbalance ... more Background & objectives: Rheumatoid artherits (RA) is a refractory disease and the imbalance between pro- and anti-inflammatory cytokines in favor of pro-inflammatory cytokines has been implicated in pathogenesis of RA. In this context, the aim of the present study was to compare the anti-inflammatory and antioxidant effects of candesartan, an angiotensin-receptor blocker, and atorvastatin in RA patients. Methods: In this single-blinded parallel randomized placebo controlled study, the patients recruited between December 2017 and May 2018 were categorized into three groups: group 1 included 15 RA patients who served as control group and received traditional therapy (+ placebo); group 2 included 15 RA patients who received traditional therapy + candesartan (8 mg/day); and group 3 included 15 patients who received traditional therapy + atorvastatin (20 mg/day) for three months. Clinical status in RA patients was evaluated by Disease Activity Score 28 (DAS28), Health Assessment Questionnaire-Disability Index (HAQ-DI) and morning stiffness before and three months after treatment. All groups were subjected to biochemical analysis of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β) and malondialdehyde (MDA) before and three months after treatment. Results: Both candesartan and atorvastatin treated groups showed significant decrease in serum levels IL-1β and TNF-α, acute-phase reactants (CRP and ESR), number of swollen joint and patient global assessment. This was also associated with improvement in disease activity and quality of life regarding DAS28 and HAQ-DI as compared to baseline data and the control group. Atorvastatin group showed significant decrease in the serum level of oxidative stress marker (MDA). Interpretation & conclusions: Both candesartan and atorvastatin showed anti-inflammatory effect and immunomodulatory effects leading to improvement in clinical status and disease activity in RA patients. However, atorvastatin was superior to candesartan through its anti-oxidant effect.
IntroductionCorona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to ... more IntroductionCorona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.Aim of Study1-To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID192-To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effectsPatients and Population265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is inc...
The development of drug resistance remains the major obstacle to clinical efficacy of cancer chem... more The development of drug resistance remains the major obstacle to clinical efficacy of cancer chemotherapy. Consequently, finding new therapeutic options for cancerous patients is an urgent need. Sixty newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients were recruited from Clinical Oncology Department, Faculty of Medicine, Menoufia University, Egypt prospectively randomized to three groups ( n = 20 for each group). Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the first five days of cycle}, group two received lansoprazole (LAN) 60 mg p.o. bid for only one week before starting each of cycle + R-CHOP and group three received famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R-CHOP for six cycles. Blood samples were obtained for biochemical analysis of transforming growth factor-β (TGF-β), Basic fibroblast growth factor (bFGF), interleukin-9 (IL-9), nuclear factor-kappa B (NF-κB) and Caspase 3 before and after six cycles of therapy. The obtained data showed that LAN and FAM resulted in significant decrease in (LDH, TGF-β, bFGF and IL-9, respectively) and significant increase in (Caspase-3). In addition, LAN produced a significant elevation in the response rate compared to the control group or the FAM group. Both LAN and FAM as adjuvant therapy represents a promising anticancer strategy in DLBCL by modulation of malignancy homeostasis mechanisms and boosting chemotherapy antitumor effects without further toxicity. In addition, LAN has a synergetic effect in improving the response rate. Trial registration Clinical Trial.gov Identifier: NCT0364707.
Asian Journal of Pharmaceutical and Clinical Research
Objective: Endothelial dysfunction is afflicted to the maturation of arteriosclerosis and type 2 ... more Objective: Endothelial dysfunction is afflicted to the maturation of arteriosclerosis and type 2 diabetes mellitus (T2DM) vascular complications. This study designed to evaluate the impact of fenofibrate adjuvant therapy on endothelial dysfunction and cardiovascular risk in patients with T2DM. Methods: Seventy-five subjects were recruited from the Internal Medicine Department of Tanta University Hospital. The participants were classified into three groups: Group 1 (control group), 25 healthy subjects; Group 2, 25 T2DM patients received glimepiride/metformin (2:500 mg/day); and Group 3, 25 T2DM patients received glimepiride/metformin (2:500 mg/day)+fenofibrate (300 mg/day). Patients were assessed before and 3 months after intervention for the determination of body mass index (BMI), blood pressure, glycemic picture (hemoglobin A1C % and homeostatic model assessment of insulin resistant), lipid panel, Castelli’s risk index (CRI-I and CRI-II), albumin-to-creatinine ratio (ACR), and endo...
Uploads
Papers by Sahar Hegazy